Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Highly Accessed Editorial

Goldilocks, vitamin D and sarcoidosis

Robert P Baughman12* and Elyse E Lower1

Author Affiliations

1 Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA

2 1001 Holmes Building, Eden Ave, Cincinnati, OH 45267-0565, USA

For all author emails, please log on.

Arthritis Research & Therapy 2014, 16:111  doi:10.1186/ar4568


See related research by Saidenberg-Kermanac’h et al., http://arthritis-research.com/content/16/2/R78

The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/16/3/111


Received:2 April 2014
Accepted:14 May 2014
Published:23 May 2014

© 2014 Baughman and Lower; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Abstract

While low levels of vitamin D can increase the risk for osteoporosis, excessive amounts of vitamin D may also be problematic. Hypercalcemia and hypercalcuria due to increased vitamin D activity occur in a significant proportion of sarcoidosis patients. Saidenberg-Kermanac’h and colleagues compared vitamin D levels with bone fragility fractures in their sarcoidosis clinic. They found that a 25-(OH) vitamin D level between 10 and 20 ng/ml was associated with the lowest risk of bone fractures and paradoxically higher levels increased the risk of bone fractures. Using less vitamin D supplementation may simultaneously lower the risk for bone fracture and hypercalcemia in sarcoidosis.

Editorial

In the previous issue, Saidenberg-Kermanac’h and colleagues provide more information regarding the complexity of vitamin D activity in sarcoidosis [1]. A few years ago, vitamin D was declared the nutrient of the decade. This was heady stuff for a sterol that was originally felt important only in preventing rickets. Studies have demonstrated its key role in calcium absorption and bone growth. Beyond that, vitamin D has been considered an important sterol in various aspects of health. Low levels of vitamin D have been associated with increased risk for cancer, type 2 diabetes, and heart disease.

Most of these observations have been based on measurements of 25-(OH)-vitamin D3 (ergocalcitrol). This sterol is converted by 1-alpha hydroxylase to 1,25-(OH)2-vitamin D3 (calcitrol), the active form of vitamin D. This conversion occurs in the kidney and patients with chronic renal failure require calcitrol replacement.

In tuberculosis, vitamin D supplementation has been recommended in patients because vitamin D is crucial in the granulomatous reaction against the organism. However, what may be good for tuberculosis eradication may not be good for sarcoidosis. It has been noted that excessive amounts of vitamin D are associated with a worse clinical outcome in sarcoidosis [2]. In granulomas, there may be increased activity of 1-alpha hydroxylase. As part of the Th-1 immune response, calcitrol has a paracrine effect within the granuloma. In some cases, this leads to excessive calcitrol, resulting in hypercalcuria or hypercalcemia [3]. At least 10% of sarcoidosis patients have hypercalcemia, half of whom can develop associated renal dysfunction [3,4]. In some cases, hypercalcemic renal failure can be reversed by simply withdrawing vitamin D supplementation [3]. There are case reports of excessive vitamin D replacement leading to hypercalcemia in patients with mycobacterial infections [5].

The sarcoidosis patient may be treated with glucocorticoids, sometimes for years. Obviously, long-term glucocorticoid administration places the patient at risk for developing osteoporosis [6,7]. In rheumatoid arthritis, patients undergoing prolonged glucocorticoid treatment are recommended to receive calcium and vitamin D replacement [8]. While this is the cornerstone of prevention of osteoporosis, the role of calcium and vitamin D replacement in sarcoidosis remains unclear [9].

Into this quandary comes the study by Saidenberg-Kermanac’h and colleagues reported in the previous issue of Arthritis Research & Therapy[1]. After studying a large cohort of sarcoidosis patients from their clinic, the authors found that fragility fractures occurred in nearly a quarter of them. The fracture risk was increased for those treated with corticosteroids. Although low levels of ergocalcitrol was an independent risk for osteoporosis, ironically high levels of ergocalcitrol were also associated with an increased risk for osteoporosis. They found that ergocalcitrol levels of 10 to 20 ng/ml was associated with the lowest fracture risk for patients. This J shaped risk for bone fragility has been noted in non-sarcoidosis patients, although the proposed target levels are higher for these patients [10]. For the clinician treating sarcoidosis, one has to balance not only the risk for osteoporosis, but also the risk for hypercalcemia and renal failure (Figure 1).

thumbnailFigure 1. Schematic depicting vitamin D metabolism in the body from ergocalcitrol to calcitrol. The conversion is enhanced by increased activity of 1-alpha hydroxylase activity in the granuloma of sarcoidosis patients. The untoward consequences of low or high vitamin D activity are summarized at the bottom of the figure.

One possible explanation for the lower ideal ergocalcitrol level in sarcoidosis is the enhanced activity of 1-alpha hydroxylase in sarcoidosis granulomas. The authors did not provide information regarding calcitrol levels in their patients. The proportion of calcitrol to ergocalcitrol appears to be higher in sarcoidosis compared to non-sarcoidosis conditions. In one study of 270 sarcoidosis patients, 80% had low ergocalcitrol levels, but less than 1% had low calcitrol levels. In fact, that study found that 10% of patients had elevated calcitrol levels [3]. Those with elevated calcitrol were more likely to have a history of hypercalcemia or hypercalcuria. Higher levels of calcitrol have been associated with more advanced pulmonary sarcoidosis [2].

The other potential benefits of vitamin D replacement in sarcoidosis are unclear. Should sarcoidosis patients with low ergocalcitrol but normal calcitrol levels be prescribed vitamin D supplementation to reduce their risk for cancer and type 2 diabetes? If so, do they increase their risk for hypercalcemia or hypercalcuria? Could this increased vitamin D intake raise the functional level of vitamin D even higher and therefore increase the risk for osteoporosis?

To paraphrase Goldilocks, one does not want too little or too much vitamin D. You want just the right amount.

References

  1. Saidenberg-Kermanac'h N, Semerano L, Nunes H, Sadoun D, Guillot X, Boubaya M, Naggara N, Valeyre D, Boissier MC: Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study of 142 patients.

    Arthritis Res Ther 2014, 16:R78. PubMed Abstract | BioMed Central Full Text OpenURL

  2. Kavathia D, Buckley JD, Rao D, Rybicki B, Burke R: Elevated 1,25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis.

    Respir Med 2010, 104:564-570. PubMed Abstract | Publisher Full Text OpenURL

  3. Baughman RP, Janovcik J, Ray M, Sweiss N, Lower EE: Calcium and vitamin D metabolism in sarcoidosis.

    Sarcoidosis Vasc Diffuse Lung Dis 2013, 30:113-120. PubMed Abstract OpenURL

  4. Mahévas M, Lescure FX, Boffa JJ, Delastour V, Belenfant X, Chapelon C, Cordonnier C, Makdassi R, Piette JC, Naccache JM, Cadranel J, Duhaut P, Choukroun G, Ducroix JP, Valeyre D: Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients.

    Medicine (Baltimore) 2009, 88:98-106. Publisher Full Text OpenURL

  5. Lavender TW, Martineau AR, Quinton R, Schwab U: Severe hypercalcaemia following vitamin D replacement for tuberculosis-associated hypovitaminosis D.

    Int J Tuberc Lung Dis 2012, 16:140. PubMed Abstract | Publisher Full Text OpenURL

  6. Rizzato G, Montemurro L: Reversibility of exogenous corticosteroid-induced bone loss.

    Eur Respir J 1993, 6:116-119. PubMed Abstract OpenURL

  7. Adler RA, Funkhouser HL, Petkov VI, Berger MM: Glucocorticoid-induced osteoporosis in patients with sarcoidosis.

    Am J Med Sci 2003, 325:1-6. PubMed Abstract | Publisher Full Text OpenURL

  8. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG: American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.

    Arthritis Care Res (Hoboken) 2010, 62:1515-1526. Publisher Full Text OpenURL

  9. Sweiss NJ, Lower EE, Korsten P, Niewold TB, Favus MJ, Baughman RP: Bone health issues in sarcoidosis.

    Curr Rheumatol Rep 2011, 13:265-272. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  10. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC: Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial.

    JAMA 2010, 303:1815-1822. PubMed Abstract | Publisher Full Text OpenURL